Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Consensus

—

Average target

$177.00

Implied upside

—

Analysts

—

Why Is BIIB Down Today?

Biogen shares declined 1.62% today despite positive clinical data, suggesting the market may have already priced in the company's recent achievements or investors are taking profits ahead of the weekend. The company announced publication of Phase 3 pediatric trial data for EMPAVELI showing encouraging efficacy in rare kidney diseases, but the modest stock reaction indicates limited surprise value from the announcement.

Bottom line: While Biogen's EMPAVELI clinical data is genuinely encouraging and represents a meaningful achievement in rare kidney disease treatment, the market's muted response suggests investors are taking a wait-and-see approach on commercial impact. Investors should monitor upcoming revenue guidance and prescriber adoption metrics to determine whether these clinical wins translate into meaningful financial upside for shareholders.